Hematological Malignancy
68
12
14
30
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.8%
6 terminated out of 68 trials
83.3%
-3.2% vs benchmark
7%
5 trials in Phase 3/4
17%
5 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (68)
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Membrane Target Detection for Leukemia Treatment
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Micro Assays for HemATology Malignancies Antibody Treatment
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials
Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies
Investigation of the Effects of Prehabilitation Education Delivered Through a Mobile Compatible Website on Quality of Life and Symptoms in Patients Undergoing Hematopoietic Stem Cell Transplantation
CXCR4-targeted PET/CT Imaging in Hematological Malignancies
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies